Is compounded semaglutide still legal in 2026?
The shortage ended, the FDA is tightening the rules, and a 503B bulks-list proposal landed in April 2026. What's still legal, what changed, and what to do.
Where compounded semaglutide stands in July 2026
The short version: compounded semaglutide has not been banned outright, but the legal ground it stands on is much narrower than during the shortage. It remains available through 503A pharmacies that dispense against a valid, patient-specific prescription for a documented clinical need. What's no longer permitted is the shortage-era practice of compounding "essentially a copy" of the approved product at scale. The regulatory direction is clearly tightening, and reputable telehealth programs have adapted their pharmacy networks accordingly.
How the rules changed
The compounded GLP-1 boom was built on a specific legal hook: when a drug is on the FDA's shortage list, compounders may make copies. Semaglutide and tirzepatide went on that list in 2022 amid surging demand, enabling widespread compounding at roughly $150–$300/month versus $1,000-plus brand pricing. The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in February 2025, then set wind-down deadlines. Industry groups sued to block enforcement but courts denied their injunctions in 2025, and the deadlines held.
503A vs 503B compounding today
The distinction between the two compounding pathways now carries real weight. 503A pharmacies compound for an individual patient against a specific prescription, regulated primarily by state boards — this pathway continues, though it can't be used to mass-produce copies. 503B outsourcing facilities compound larger batches under FDA oversight and depend on either shortage status or the 503B bulks list, both of which have closed for semaglutide. In practice, legitimate telehealth access now runs through 503A patient-specific compounding.
| Pathway | Status for semaglutide (July 2026) |
|---|---|
| 503A (patient-specific) | Legal with a valid individual prescription; no mass copies |
| 503B (bulk / outsourcing) | Closed post-shortage; April 2026 proposal would bar bulks-list use |
| Shortage-based exception | Ended (shortage resolved Feb 2025) |
The April 2026 bulks-list proposal
On July 6, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, arguing there's no clinical need for outsourcing facilities to compound them from bulk drug substance now that approved products are available. A public comment period ran through late June 2026. Importantly, this is a proposal, not a finalized ban, and it targets 503B bulk compounding — the 503A patient-specific pathway continues. The FDA also cited safety concerns, including hundreds of adverse-event reports tied to dosing errors with multi-dose compounded vials.
What this means if you use compounded semaglutide
Three practical steps. First, ask your pharmacy directly what legal basis supports your prescription today — a legitimate 503A pharmacy dispensing against your individual prescription can answer clearly. Second, verify the pharmacy is named and licensed (state board for 503A), and be wary of any program that dodges sourcing questions or implies the compounded product is FDA-approved (it isn't). Third, know your alternatives: if access tightens, FDA-approved options include brand Wegovy/Zepbound, the new oral Wegovy at ~$149/month, LillyDirect vials, and — for eligible Medicare beneficiaries — the $50 Bridge program. The compounded market still exists in July 2026, but the smart move is to buy only from transparent, verifiable 503A programs and to keep an eye on the finalized rule.
Frequently asked questions
Is compounded semaglutide legal in 2026?
As of July 2026, compounded semaglutide remains legal only through 503A pharmacies dispensing against a valid, patient-specific prescription — not as mass-produced copies. The FDA resolved the shortage in February 2025, ending the shortage-based pathway, and proposed further 503B restrictions in April 2026. It is not FDA-approved.
Did the FDA ban compounded semaglutide?
Not outright. The FDA ended the shortage-based compounding pathway and, on July 6, 2026, proposed removing semaglutide from the 503B bulks list — a proposal, not a finalized ban. 503A patient-specific compounding with a valid prescription continues.
What's the difference between 503A and 503B for GLP-1s now?
503A pharmacies compound for an individual patient against a prescription and can still dispense semaglutide with a valid script (but not mass copies). 503B bulk/outsourcing compounding of semaglutide has closed post-shortage and faces further restriction under the April 2026 proposal.
What are my options if compounded access tightens?
FDA-approved alternatives include brand Wegovy and Zepbound, the new oral Wegovy pill (~$149/month), LillyDirect self-pay vials ($299–$449), and — for eligible Medicare beneficiaries — the $50/month GLP-1 Bridge program that began July 1, 2026.
How do I know my compounded semaglutide is legitimate?
Ask the pharmacy to state the legal basis for your prescription, confirm it's a named, state-licensed 503A pharmacy dispensing against your individual prescription, and avoid any program that dodges sourcing questions or claims the compounded product is FDA-approved.
References
- U.S. FDA. FDA clarifies policies for compounders as GLP-1 supply stabilizes.
- U.S. FDA. Proposed exclusion of semaglutide, tirzepatide, liraglutide from 503B bulks list, July 6, 2026.
- Pharmacy Times. FDA moves to permanently close the door on compounded GLP-1s, 2026.
- Drug Topics. GLP-1 no longer on FDA drug shortage list, 2026.
Clinical and regulatory figures from published trials, FDA, and CMS communications; pricing from provider-advertised and manufacturer rates checked July 2026 and subject to change. Educational, not medical or financial advice.